Literature DB >> 35729602

Retraction Note: Long non-coding RNA TPT1-AS1 promotes cell growth and metastasis in cervical cancer via acting AS a sponge for miR-324-5p.

Hui Jiang1,2, Guanqun Huang3, Nianzhang Zhao4, Ting Zhang2, Mengni Jiang2, Yueming He2, Xinke Zhou5, Xianhan Jiang6.   

Abstract

Entities:  

Year:  2022        PMID: 35729602      PMCID: PMC9215061          DOI: 10.1186/s13046-022-02418-x

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


× No keyword cloud information.
Retraction Note: J Exp Clin Cancer Res 37, 169 (2018) https://doi.org/10.1186/s13046-018-0846-8 The Editor-in-Chief has retracted this article at the corresponding author's request. After publication, concerns were raised regarding image overlap between the figures in this article and previous publications from different groups, specifically: Fig. 2d appears to overlap with Fig. 8b in [1] Fig. 3e appears to overlap with Fig. 4c in [2] Additionally, in Fig. S1, the mean tumour weights in the TPT1-AS1 and sh-Vector groups appear to exceed the recommended tumour weight limit of 10% of initial bodyweight. No statement on Ethics approval for the use of animals is present in the article. The authors have been unable to retrieve the original data or ethics documents to address these concerns. Guanqun Huang, Nianzhang Zhao, Ting Zhang, Mengni Jiang, Yueming He and Xinke Zhou agree to this retraction. Hui Jiang and Xianhan Jiang have not responded to any correspondence from the publisher about this retraction.
  2 in total

1.  MicroRNA-1297 inhibits metastasis and epithelial-mesenchymal transition by targeting AEG-1 in cervical cancer.

Authors:  Zengyan Wang; Shanyang He; Peng Guo; Xu Guo; Jingxuan Zheng
Journal:  Oncol Rep       Date:  2017-09-20       Impact factor: 4.136

2.  MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.

Authors:  Qiuran Xu; Xin Liu; Zhikui Liu; Zhenyu Zhou; Yufeng Wang; Jianfeng Tu; Lijie Li; Hangxing Bao; Liu Yang; Kangsheng Tu
Journal:  Mol Cancer       Date:  2017-06-12       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.